Fabbio Patrick
Transactions
16
Companies
4
Filings
14
CIK
0001658859
Recent Transactions
- Award
- Award
- Award
- Tax Payment
- Award
- Award
- Award
- Tax Payment
Class B Common Stock, par value $.01 per share
2022-12-21$1.76/sh−27,928→ 335,175 total - Award
Class B Common Stock, par value $.01 per share
2022-02-01+363,103→ 363,103 total - Award
- Award
Non-Qualified Stock Option (Right to Buy)
2020-03-02+82,214→ 82,214 total - Award
Non-Qualified Stock Option (Right to Buy)
2019-03-01+90,750→ 90,750 total - Award
Non-Qualified Stock Option (Right to Buy)
2018-03-01+94,875→ 94,875 total - Award
Non-Qualified Stock Option (Right to Buy)
2017-03-01+82,500→ 82,500 total - Award
Non-Qualified Stock Option (right to buy)
2016-03-01$4.52/sh+82,500→ 82,500 total - Award
Non-Qualified Stock Option (right to buy)
2015-12-01$6.77/sh+125,000→ 125,000 total
Companies
4Recent Filings
14- 4
Fabbio Patrick
Apr 23, 2025
- 4
Fabbio Patrick
Jan 28, 2025
- 4
Fabbio Patrick
Jan 23, 2025
- 4
Fabbio Patrick
Jan 23, 2024
- 4
Fabbio Patrick
Jan 30, 2023
- 4
Fabbio Patrick
Dec 23, 2022
- 4
Fabbio Patrick
Feb 3, 2022
- 4
Fabbio Patrick
Sep 20, 2021
- 4
Fabbio Patrick
Mar 4, 2020
- 4
Fabbio Patrick
Mar 5, 2019
- 4
Fabbio Patrick
Mar 2, 2018
- 4
PROGENICS PHARMACEUTICALS INC
Mar 7, 2017
- 4
PROGENICS PHARMACEUTICALS INC
Mar 3, 2016
- 4
PROGENICS PHARMACEUTICALS INC
Dec 3, 2015
Address
C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK, NY, 10010